Understanding Cellectis Share Capital and Voting Rights
Cellectis has released the latest information regarding its share capital and voting rights, a crucial element for both potential investors and existing shareholders. With the shares listed on Euronext Growth, it's important to keep abreast of any changes that affect overall investment value and voting power.
Cellectis Overview
Cellectis is a biotechnology firm that specializes in developing immunotherapies based on its proprietary platform technology. The company aims to harness the potency of the immune system to combat cancer and other critical diseases. Understanding share details is vital for investors as they look to assess their stake in the company.
Current Share Information
As of March 31, 2025, Cellectis holds an impressive total of 100,290,078 shares in circulation. Investors take note: the number of voting rights tied to these shares is 89,046,759. This discrepancy is significant, as it illustrates the possibility of non-voting shares which can impact decision-making in shareholder meetings.
Shares and Voting Rights Explained
The difference between the total number of shares and the total number of voting rights prompts questions around the structure of share ownership and voting capabilities within the company. Generally, companies like Cellectis may issue various classes of shares, some of which may not carry voting rights. This fact can affect control dynamics within the company's shareholder structure.
Investor and Media Relations
For investors interested in more detailed information or inquiries, Cellectis provides an accessible contact point. Media inquiries can be directed to Pascalyne Wilson, Director of Communications, who can be reached at +33 (0)7 76 99 14 33 or by email at media@cellectis.com. Patricia Sosa Navarro, Chief of Staff to the CEO, is also available at +33 (0)7 76 77 46 93.
Investor Relations Contact
Arthur Stril serves as the Chief Financial Officer & Chief Business Officer and is available for investor relations inquiries at investors@cellectis.com. His role ensures that investors receive timely updates and necessary information that might impact their investment decisions.
Attachments and Additional Resources
For those interested in further documentation, Cellectis has made available an attachment that outlines voting rights as of March 2025. This resource can be particularly useful for investors looking to understand the voting landscape. The document can be accessed via the link: Voting Rights Document.
Frequently Asked Questions
What is the significance of Cellectis's voting rights?
Voting rights give shareholders a say in important corporate actions, influencing decisions on mergers, appointments, and other significant issues.
How are the shares structured within Cellectis?
Cellectis may have multiple classes of shares, which can include non-voting options that affect overall shareholder power.
Who can investors contact for more details?
Investors can reach out to Arthur Stril or Pascalyne Wilson for inquiries related to investor relations or media communications.
Why is share capital information important for investors?
Understanding share capital is crucial as it highlights the company's financial health and stock performance, guiding investment choices.
Where can I find more detailed reports about Cellectis?
Detailed reports and updates are typically found in press releases and investor communications available on Cellectis' official channels.
